Under the terms of the agreement, Bristol-Myers Squibb will make payments aggregating to $50 million that consist of an option fee for the right to acquire F-star Alpha Ltd.,
Wasn't our deal with DIOS potentially up to 50 million dollars? Whatever happened with that? What about Medipharm?
cheynew, PPHM should NOT do that for all the reasons I just explained in in this post IMO.
However, a variation of that would NOT be misplace in PPHM's creative solutions portfolio (like they did with the K&L Gates PPHMP preferred offering).
They could sell "preferred partnership" or "preferred buy-out" or "preferred collaboration" or even "preferred acquisition" rights.
The concept would be simple and straight forward: In equal offerings a BP's amount of "preferred rights" for the type of proposition (partnership, collaboration, acquisition, etc) gives you priority.
So if you want to run a collaboration in, say Ebola or Liver Cancer, and you match the offer of your competitor(s) then you have priority if that competitor doesn't up the offer. That is a BIG advantage because you never have to up the offer yourself, it is always the competition, you just have to say I match as long as you are willing to follow.
That would generate cash and actually already start a competition between potential candidate. Now suppose for a moment they would issue that in the form of a PPHM(x?) on NASDAQ. So we could buy those rights to and BP's in need of them would have to buy them via NASDAQ. So the BP's stay anonymous.
You see the possibilities? I am sure a company as K&L Gates could do much more with this because I just invented it here at my keyboard in a 5 min reply to your post and it may need tuning or legal checks, but it certainly would give the COUPONS of those PPHMx shares a value every time PPHM would come in a competing-bidding situation on whatever it wants to oppose BP's against each other. Not a bad attitude if you HAVE something. And PPHM HAS something: Bavituximab.
News 
Market Data 
Discover 
AI
